Precigen

Precigen is a commercial-stage biopharmaceutical company focused on developing and delivering precision medicines for difficult-to-treat diseases with high unmet patient need. Its work combines therapeutic and technology platforms to advance targeted treatments, with research and clinical programs supported by scientific publications and data presented at medical and health economics conferences.

The company’s current marketed medicine is PAPZIMEOS, which Precigen describes as the first FDA-approved therapy for adults with recurrent respiratory papillomatosis (RRP). Its website provides prescribing information and resources for physicians and patients, alongside information about the medicine’s development and clinical evidence. Precigen also highlights its AdenoVerse platform, which recently received FDA Platform Technology Designation, and reports research into non-replicating adenoviral vector-based immunotherapy for RRP.

Beyond its medicines and pipeline, Precigen offers an expanded access policy and shares updates through press releases, events, and investor materials. Headquartered in Germantown, Maryland, the company also recruits professionals and postdoctoral researchers interested in contributing to science, medicine, and patient care.